Bo Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bo Xu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Yikai Shao
Center for Obesity and Hernia Surgery, Department of General Surgery, Huashan Hospital, Shanghai, China
6 shared publications - Rong Hua
Center for Obesity and Hernia Surgery, Department of General Surgery, Huashan Hospital, Shanghai, China
4 shared publications - Qiwei Shen
Center for Obesity and Hernia Surgery, Department of General Surgery, Huashan Hospital, Shanghai, China
3 shared publications - Qiyuan Yao
Center for Obesity and Hernia Surgery, Department of General Surgery Huashan Hospital, Fudan University Shanghai China
3 shared publications - Xiaojian Fu
Center for Obesity and Hernia Surgery, Department of General Surgery, Huashan Hospital, Shanghai, China
3 shared publications - Chong Cao
Center for Obesity and Hernia Surgery, Department of General Surgery, Huashan Hospital, Shanghai, China
2 shared publications
Latest Publications
- 31 August 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (10) , 5145-5153
Weight Loss Threshold and Inflection Points for Biochemical Remission of Male Obesity-Associated Secondary Hypogonadism After Sleeve Gastrectomy
- 31 August 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (10) , 5145-5153
Weight Loss Threshold and Inflection Points for Biochemical Remission of Male Obesity-Associated Secondary Hypogonadism After Sleeve Gastrectomy
- Open Access
- 1 June 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1746572
Targeting hepcidin to restore oral iron efficacy after vertical sleeve gastrectomy
Background: Metabolic bariatric surgery (MBS) such as Vertical Sleeve Gastrectomy (VSG) is the most effective intervention for obesity but commonly results in iron deficiency, inadequately managed by oral iron supplementation. This study aimed to investigate mechanisms underlying the inefficacy of oral iron supplementation post-VSG, evaluate clinical relevance through patient studies, and test the therapeutic potential of curcumin, a hepcidin inhibitor, to improve iron management. Methods: Diet-induced obese mice underwent VSG or sham surgery and received either regular-iron or iron-rich diets postoperatively, with or without curcumin supplementation. Systemic and tissue iron metrics, expressions of genes and proteins involved in iron metabolism were analyzed. Clinically, we evaluated circulating hepcidin levels in VSG patients developing iron deficiency vs. matched controls without deficiency at 6-months post-surgery. Results: In mouse models, VSG induced persistent iron deficiency that could not be corrected by oral iron supplementation. VSG increased intestinal dietary iron uptake capacity, yet oral iron triggered a disproportionate rise in hepatic hepcidin. The resulting hepcidin-mediated ferroportin loss traped absorbed iron within enterocytes, hepatocytes, and macrophages, producing persistent systemic iron deficiency despite supplementation. Moreover, curcumin, a hepcidin-suppressive intervention, restored ferroportin protein, mobilized sequestered iron, and rescued serum iron indices while leaving the VSG-induced intestinal iron absorption machinery intact. In patients 6 months after VSG receiving routine oral iron supplementation, those with iron deficiency exhibit higher hepcidin than matched non-deficient controls, and hepcidin levels were inversely correlated with circulating iron levels. Conclusions: These results reframe post-VSG iron deficiency as a disorder of iron mobilization and regulation, not merely reduced absorption. Clinically, they argue for therapeutic strategies that target the hepcidin-ferroportin axis to restore the efficacy of oral iron supplementation in correcting iron deficiency following MBS.
- 1 June 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1746572
Open AccessTargeting hepcidin to restore oral iron efficacy after vertical sleeve gastrectomy
Background: Metabolic bariatric surgery (MBS) such as Vertical Sleeve Gastrectomy (VSG) is the most effective intervention for obesity but commonly results in iron deficiency, inadequately managed by oral iron supplementation. This study aimed to investigate mechanisms underlying the inefficacy of oral iron supplementation post-VSG, evaluate clinical relevance through patient studies, and test the therapeutic potential of curcumin, a hepcidin inhibitor, to improve iron management. Methods: Diet-induced obese mice underwent VSG or sham surgery and received either regular-iron or iron-rich diets postoperatively, with or without curcumin supplementation. Systemic and tissue iron metrics, expressions of genes and proteins involved in iron metabolism were analyzed. Clinically, we evaluated circulating hepcidin levels in VSG patients developing iron deficiency vs. matched controls without deficiency at 6-months post-surgery. Results: In mouse models, VSG induced persistent iron deficiency that could not be corrected by oral iron supplementation. VSG increased intestinal dietary iron uptake capacity, yet oral iron triggered a disproportionate rise in hepatic hepcidin. The resulting hepcidin-mediated ferroportin loss traped absorbed iron within enterocytes, hepatocytes, and macrophages, producing persistent systemic iron deficiency despite supplementation. Moreover, curcumin, a hepcidin-suppressive intervention, restored ferroportin protein, mobilized sequestered iron, and rescued serum iron indices while leaving the VSG-induced intestinal iron absorption machinery intact. In patients 6 months after VSG receiving routine oral iron supplementation, those with iron deficiency exhibit higher hepcidin than matched non-deficient controls, and hepcidin levels were inversely correlated with circulating iron levels. Conclusions: These results reframe post-VSG iron deficiency as a disorder of iron mobilization and regulation, not merely reduced absorption. Clinically, they argue for therapeutic strategies that target the hepcidin-ferroportin axis to restore the efficacy of oral iron supplementation in correcting iron deficiency following MBS.
- 31 October 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (12) , 5288-5297
Baseline Risk Factors and Predictive Nomogram for Short-Term Persistent Hyperuricemia Following Laparoscopic Sleeve Gastrectomy: A Dual Center Study
Introduction Although laparoscopic sleeve gastrectomy (LSG) effectively addresses obesity, its outcomes on hyperuricemia (HUA) remission remain inconsistent. We aimed to identify baseline predictors and develop a nomogram for HUA persistence six months following LSG. Methods We retrospectively analyzed patients with obesity and HUA undergoing primary LSG at Huashan Hospital. An independent validation cohort from the Affiliated Hospital of Xuzhou Medical University was included. Clinical data, including demographics, anthropometric measurements, and biochemical markers were analyzed. Logistic regression analyses identified independent predictors of persistent HUA, and a predictive nomogram was developed and externally validated. Results A total of 631 patients was enrolled in this study. Persistent HUA was observed in 41.8% (159/380) of patients in the training cohort. Multivariate analysis identified male sex (OR = 4.97, 95% CI: 2.35–10.51, P < 0.001), waist circumference (WC; OR = 1.06, 95% CI: 1.02–1.10, P = 0.006), and baseline UA levels (OR = 1.01, 95% CI: 1.01–1.02, P < 0.001) as significant predictors. The nomogram demonstrated excellent discriminative ability (AUC = 0.85, 95% CI: 0.82–0.86) and calibration. In the validation cohort, persistent HUA was observed in 35.5% (89/251), and the nomogram maintained robust predictive performance (AUC = 0.81, 95% CI: 0.76–0.82). Conclusion Male sex, increased WC, and elevated baseline UA predict postoperative persistent HUA. The nomogram provides a practical clinical tool for predicting short-term HUA non-remission post-LSG.
- 31 October 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (12) , 5288-5297
Baseline Risk Factors and Predictive Nomogram for Short-Term Persistent Hyperuricemia Following Laparoscopic Sleeve Gastrectomy: A Dual Center Study
Introduction Although laparoscopic sleeve gastrectomy (LSG) effectively addresses obesity, its outcomes on hyperuricemia (HUA) remission remain inconsistent. We aimed to identify baseline predictors and develop a nomogram for HUA persistence six months following LSG. Methods We retrospectively analyzed patients with obesity and HUA undergoing primary LSG at Huashan Hospital. An independent validation cohort from the Affiliated Hospital of Xuzhou Medical University was included. Clinical data, including demographics, anthropometric measurements, and biochemical markers were analyzed. Logistic regression analyses identified independent predictors of persistent HUA, and a predictive nomogram was developed and externally validated. Results A total of 631 patients was enrolled in this study. Persistent HUA was observed in 41.8% (159/380) of patients in the training cohort. Multivariate analysis identified male sex (OR = 4.97, 95% CI: 2.35–10.51, P < 0.001), waist circumference (WC; OR = 1.06, 95% CI: 1.02–1.10, P = 0.006), and baseline UA levels (OR = 1.01, 95% CI: 1.01–1.02, P < 0.001) as significant predictors. The nomogram demonstrated excellent discriminative ability (AUC = 0.85, 95% CI: 0.82–0.86) and calibration. In the validation cohort, persistent HUA was observed in 35.5% (89/251), and the nomogram maintained robust predictive performance (AUC = 0.81, 95% CI: 0.76–0.82). Conclusion Male sex, increased WC, and elevated baseline UA predict postoperative persistent HUA. The nomogram provides a practical clinical tool for predicting short-term HUA non-remission post-LSG.
- 7 October 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (11) , 4662-4669
Risk Factors of Iron Deficiency and Iron Deficiency Anemia After Laparoscopic Sleeve Gastrectomy: A Retrospective Cohort Study
Introduction Metabolic and bariatric surgery (MBS) can effectively improve obesity and its related complications, but it may lead to side effects such as iron deficiency (ID) and iron deficiency anemia (IDA). However, the specific risk factors for ID and IDA after laparoscopic sleeve gastrectomy (LSG) remain unclear. Methods We retrospectively enrolled 465 patients who underwent LSG from April 2014 to December 2021. The risk factors for postoperative ID and IDA were evaluated using logistic regression analysis. Patients who underwent LSG from December 2020 to December 2021 were given low-dose iron and vitamin B12 orally based on the iron-containing multivitamin supplementation throughout the year after surgery. We analyzed the incidence of postoperative ID and IDA in patients who received additional prophylactic treatment compared with those who did not. Results One hundred one (21.7%) patients were diagnosed with ID, 23(4.9%) patients with IDA, and 19 (4.1%) cases with anemia of chronic disease (ACD) before LSG. One year after LSG, 53 (11.4%) patients were diagnosed with ID, 50 (10.8%) patients with IDA, and 32 (6.9%) cases with ACD. Female sex (OR = 3.660, 95% CI 1.676 ~ 7.995, P = 0.001) and preoperative anemia (OR = 2.139, 95% CI 0.992 ~ 4.613, P = 0.052) were associated with an increased risk of ID and IDA independently. The higher level of iron saturation (OR = 0.914, 95% CI 0.887 ~ 0.942, P < 0.001) was identified as a protective factor against postoperative anemia. The incidence of ID and IDA was reported in 12.0% of patients taking 0.1 g of iron succinate and 0.5 mg of vitamin B12 orally once a day. For patients who did not receive prophylactic medication, the incidence 1 year after surgery was 12.6%, which showed no statistical difference (P = 0.858). Conclusions In conclusion, the incidence of anemia increased after LSG. Female sex and preoperative anemia are independent risk factors for ID and IDA after LSG. The higher level of iron saturation was a protective factor against postoperative anemia. Low-dose prophylactic medication does not significantly reduce the incidence of ID and IDA.
- 7 October 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (11) , 4662-4669
Risk Factors of Iron Deficiency and Iron Deficiency Anemia After Laparoscopic Sleeve Gastrectomy: A Retrospective Cohort Study
Introduction Metabolic and bariatric surgery (MBS) can effectively improve obesity and its related complications, but it may lead to side effects such as iron deficiency (ID) and iron deficiency anemia (IDA). However, the specific risk factors for ID and IDA after laparoscopic sleeve gastrectomy (LSG) remain unclear. Methods We retrospectively enrolled 465 patients who underwent LSG from April 2014 to December 2021. The risk factors for postoperative ID and IDA were evaluated using logistic regression analysis. Patients who underwent LSG from December 2020 to December 2021 were given low-dose iron and vitamin B12 orally based on the iron-containing multivitamin supplementation throughout the year after surgery. We analyzed the incidence of postoperative ID and IDA in patients who received additional prophylactic treatment compared with those who did not. Results One hundred one (21.7%) patients were diagnosed with ID, 23(4.9%) patients with IDA, and 19 (4.1%) cases with anemia of chronic disease (ACD) before LSG. One year after LSG, 53 (11.4%) patients were diagnosed with ID, 50 (10.8%) patients with IDA, and 32 (6.9%) cases with ACD. Female sex (OR = 3.660, 95% CI 1.676 ~ 7.995, P = 0.001) and preoperative anemia (OR = 2.139, 95% CI 0.992 ~ 4.613, P = 0.052) were associated with an increased risk of ID and IDA independently. The higher level of iron saturation (OR = 0.914, 95% CI 0.887 ~ 0.942, P < 0.001) was identified as a protective factor against postoperative anemia. The incidence of ID and IDA was reported in 12.0% of patients taking 0.1 g of iron succinate and 0.5 mg of vitamin B12 orally once a day. For patients who did not receive prophylactic medication, the incidence 1 year after surgery was 12.6%, which showed no statistical difference (P = 0.858). Conclusions In conclusion, the incidence of anemia increased after LSG. Female sex and preoperative anemia are independent risk factors for ID and IDA after LSG. The higher level of iron saturation was a protective factor against postoperative anemia. Low-dose prophylactic medication does not significantly reduce the incidence of ID and IDA.
- 3 March 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (4) , 1543-1546
Short-Term Outcomes of 400-cm Common Limb SADI-S in Chinese Patients with Obesity of BMI < 35 kg/m2 and Type 2 Diabetes
The aim of this study was to evaluate the short-term efficacy of single-anastomosis duodeno-ileostomy with sleeve gastrectomy (SADI-S) using a 400-cm common limb in Chinese patients with obesity of low BMI (<35 kg/m²) and type 2 diabetes (T2D). Sixteen patients who underwent SADI-S between June 2022 and November 2023 were retrospectively analyzed and evaluated at 6 and 12 months postoperatively. The primary outcome was the rate of diabetes remission (HbA1c < 6.5% without antidiabetic medications for ≥ 3 months). Secondary outcomes included excess and total weight loss (EWL and TWL) and nutritional deficiencies. At 12 months postoperatively, 80% of patients achieved diabetic remission, with mean HbA1c decreasing from 8.84 ± 1.55 to 5.93 ± 0.74%. Mean BMI decreased from 30.64 ± 2.29 to 22.91 ± 2.33 kg/m², and EWL and TWL reached 122.12% ± 44.43% and 25.01% ± 8.02%, respectively. Nutritional status remained stable with no cases of hypoalbuminemia and fewer iron and vitamin deficiencies. SADI-S with a 400-cm common limb was effective in achieving glycemic control and weight loss while reducing the risk of nutritional deficiencies in Chinese patients with obesity of low BMI and T2D.
- 3 March 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (4) , 1543-1546
Short-Term Outcomes of 400-cm Common Limb SADI-S in Chinese Patients with Obesity of BMI < 35 kg/m2 and Type 2 Diabetes
The aim of this study was to evaluate the short-term efficacy of single-anastomosis duodeno-ileostomy with sleeve gastrectomy (SADI-S) using a 400-cm common limb in Chinese patients with obesity of low BMI (<35 kg/m²) and type 2 diabetes (T2D). Sixteen patients who underwent SADI-S between June 2022 and November 2023 were retrospectively analyzed and evaluated at 6 and 12 months postoperatively. The primary outcome was the rate of diabetes remission (HbA1c < 6.5% without antidiabetic medications for ≥ 3 months). Secondary outcomes included excess and total weight loss (EWL and TWL) and nutritional deficiencies. At 12 months postoperatively, 80% of patients achieved diabetic remission, with mean HbA1c decreasing from 8.84 ± 1.55 to 5.93 ± 0.74%. Mean BMI decreased from 30.64 ± 2.29 to 22.91 ± 2.33 kg/m², and EWL and TWL reached 122.12% ± 44.43% and 25.01% ± 8.02%, respectively. Nutritional status remained stable with no cases of hypoalbuminemia and fewer iron and vitamin deficiencies. SADI-S with a 400-cm common limb was effective in achieving glycemic control and weight loss while reducing the risk of nutritional deficiencies in Chinese patients with obesity of low BMI and T2D.
- 9 August 2015
- Published by Springer Nature in Obesity Surgery
- Vol. 25 (10) , 1966-1975
A Comparative Study of the Effect of Gastric Bypass, Sleeve Gastrectomy, and Duodenal–Jejunal Bypass on Type-2 Diabetes in non-Obese Rats
We compared the therapeutic effects of Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and duodenal–jejunal bypass (DJB) on type-2 diabetes mellitus (T2DM) in non-obese rats using clamp testing. Goto–Kakizaki rats (non-obese rats with T2DM) underwent surgery: RYGB, SG, or DJB. Rats were observed for 8 weeks after surgery to evaluate weight changes. Levels of glucose, insulin, and glucagon-like peptide (GLP)-1 were determined 2, 4, 6, and 8 weeks after surgery. An oral glucose tolerance test (OGTT) and clamp test was used to evaluate glucose tolerance and insulin resistance. Rats in RYGB, SG, and DJB groups weighed significantly less than sham-group rats 6 and 8 weeks after surgery. Fasting blood glucose levels of RYGB, SG, and DJB rats were significantly lower than preoperative levels. One month after surgery, the area under the curve of the OGTT (in mmol•h/L) for RYGB, SG, DJB, and sham surgery groups was 38.9 ± 5.9, 50.9 ± 2.9, 46.8 ± 3.3, and 67.4 ± 6.0, respectively; there was no significant difference in glucose levels of SG and DJB groups. Glucose infusion rates (in mg/(kg•min)) were 18.3 ± 2.7, 17.2 ± 2.1, and 16.8 ± 1.9 in hyperinsulinemic–euglycemic-clamped RYGB, DJB, and SG rats, respectively, 8 weeks after surgery. The rate in the sham surgery group was 6.3 ± 0.9. Area under plasma insulin curves 8 weeks after surgery in hyperglycemic-clamped RYGB, DJB, SG, and sham surgery rats (in mU•h/L) were 98.8 ± 7.0, 84.4 ± 6.1, 89.0 ± 7.1, and 22.6 ± 2.6, respectively. The three surgical methods described alleviated T2DM and reduced insulin resistance in non-obese rats with T2DM.
- 9 August 2015
- Published by Springer Nature in Obesity Surgery
- Vol. 25 (10) , 1966-1975
A Comparative Study of the Effect of Gastric Bypass, Sleeve Gastrectomy, and Duodenal–Jejunal Bypass on Type-2 Diabetes in non-Obese Rats
We compared the therapeutic effects of Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and duodenal–jejunal bypass (DJB) on type-2 diabetes mellitus (T2DM) in non-obese rats using clamp testing. Goto–Kakizaki rats (non-obese rats with T2DM) underwent surgery: RYGB, SG, or DJB. Rats were observed for 8 weeks after surgery to evaluate weight changes. Levels of glucose, insulin, and glucagon-like peptide (GLP)-1 were determined 2, 4, 6, and 8 weeks after surgery. An oral glucose tolerance test (OGTT) and clamp test was used to evaluate glucose tolerance and insulin resistance. Rats in RYGB, SG, and DJB groups weighed significantly less than sham-group rats 6 and 8 weeks after surgery. Fasting blood glucose levels of RYGB, SG, and DJB rats were significantly lower than preoperative levels. One month after surgery, the area under the curve of the OGTT (in mmol•h/L) for RYGB, SG, DJB, and sham surgery groups was 38.9 ± 5.9, 50.9 ± 2.9, 46.8 ± 3.3, and 67.4 ± 6.0, respectively; there was no significant difference in glucose levels of SG and DJB groups. Glucose infusion rates (in mg/(kg•min)) were 18.3 ± 2.7, 17.2 ± 2.1, and 16.8 ± 1.9 in hyperinsulinemic–euglycemic-clamped RYGB, DJB, and SG rats, respectively, 8 weeks after surgery. The rate in the sham surgery group was 6.3 ± 0.9. Area under plasma insulin curves 8 weeks after surgery in hyperglycemic-clamped RYGB, DJB, SG, and sham surgery rats (in mU•h/L) were 98.8 ± 7.0, 84.4 ± 6.1, 89.0 ± 7.1, and 22.6 ± 2.6, respectively. The three surgical methods described alleviated T2DM and reduced insulin resistance in non-obese rats with T2DM.